Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–4 of 4 results
Advanced filters: Author: "Thomas Mandrup-Poulsen" Clear advanced filters

  • Promising drugs to treat diabetes stumble in the latter stages of clinical testing. Thomas Mandrup-Poulsen explains why — and how to fix it.

    • Thomas Mandrup-Poulsen
    Comments & Opinion
    Nature
    Volume: 485, P: S17

  • Although the mechanisms of β-cell failure in type 2 diabetes mellitus remain debated, islet inflammation is implicated and the cytokine interleukin-1β has emerged as a master regulator of this process. The potential role of anakinra—a recombinant human IL-1-receptor antagonist—in the treatment of type 2 diabetes mellitus is discussed.

    • Marc Y Donath
    • Thomas Mandrup-Poulsen
    Reviews
    Nature Clinical Practice Endocrinology & Metabolism
    Volume: 4, P: 240-241

  • IAPP, a hormone secreted together with insulin and deposited in pancreatic islets in type 2 diabetes, can induce macrophage processing of interleukin 1 linked to beta-cell destruction in type 2 diabetes.

    • Thomas Mandrup-Poulsen
    News & Views
    Nature Immunology
    Volume: 11, P: 881-883

  • Interleukin 1 (IL-1) has important functions in innate and adaptive immunity. Blocking IL-1 action has clinical efficacy in many inflammatory diseases, including type 2 diabetes mellitus. Here, the authors review the mechanisms of IL-1 action that lead to β-cell failure and the rationale for use of IL-1 antagonists in type 1 diabetes mellitus.

    • Thomas Mandrup-Poulsen
    • Linda Pickersgill
    • Marc Yves Donath
    Reviews
    Nature Reviews Endocrinology
    Volume: 6, P: 158-166